SCHEMBL2313692

SCHEMBL2313692

O=C(O)C1CCCN1c1nc2ccccc2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.60
CHRNA7 P36544 1/20 0.53
HTR3A P46098 1/20 0.53
KMT2A Q03164 2/20 0.51
HSD17B10 Q99714 1/20 0.51
LMNA P02545 6/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.50
TSHR P16473 2/20 0.50
HTT P42858 2/20 0.50
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HCRTR1 O43613 2/20 0.47
HCRTR2 O43614 2/20 0.47
GABRP O00591 1/20 0.45
GABRD O14764 1/20 0.45
GABRA1 P14867 1/20 0.45
GABRB1 P18505 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2316032 1.00 ELANE (0.60) ELANECHRNA7HTR3AKMT2AHSD17B10
SCHEMBL7685083 0.96 ELANE (0.56) ELANECHRNA7HTR3AKMT2AHSD17B10
SCHEMBL6733860 0.96 ELANE (0.56) ELANECHRNA7HTR3AKMT2AHSD17B10
Hydrochloric Acid SCHEMBL7654203 0.95 ELANE (0.55) ELANECHRNA7HTR3AKMT2AHSD17B10
SCHEMBL5672094 0.85 ELANE (0.53) ELANECHRNA7HTR3AKMT2ALMNA
SCHEMBL5673336 0.85 ELANE (0.53) ELANECHRNA7HTR3AKMT2ALMNA
SCHEMBL7846334 0.85 ELANE (0.67) ELANECHRNA7HTR3AKMT2ALMNA
SCHEMBL27479845 0.82 LMNA (0.51) ELANECHRNA7HTR3AKMT2ALMNA
SCHEMBL6737804 0.80 GABRP (0.50) ELANEKMT2AHSD17B10SMN1; SMN2MAPT
SCHEMBL6738108 0.79 GABRP (0.51) ELANEHCRTR1HCRTR2GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 ELANE 2037/4885CHRNA7 4608/4885HTR3A 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.